A buildup of fat-like lipid molecules may help to promote the inability of dopaminergic neurons, the nerve cells that are lost in people with Parkinson’s disease, to divide and grow as they should, researchers suggest. Further understanding of the role of lipids in neurodegeneration “has the potential to open…
News
Mutations that inactivate a gene called ITSN1 are associated with an increased risk of Parkinson’s disease, particularly at younger ages, a large-scale database study reports. Its researchers speculated that the protein encoded by the ITSN1 gene or related proteins might be viable targets to treat Parkinson’s. The study, “…
Sensor-equipped shoes — called NUSHU smart shoes — that are designed to support people with walking difficulties due to Parkinson’s disease and other neurological conditions have received the CE mark of approval in the Europe Union (EU). The shoes perform clinical-grade gait analysis in real time, with biofeedback given…
A clinical trial will use a noninvasive, ultrasound-based technology to better understand how Parkinson’s disease develops and progresses at the molecular level. The technology, developed by researchers at Rice University in Houston, allows proteins to flow from the brain into the bloodstream, and was previously used in a mouse…
About 15% of Parkinson’s disease cases are tied to genetic variants and nearly all are associated with the LRRK2 and GBA1 genes, initial data from the Rostock International Parkinson’s Disease (ROPAD) study indicates. Launched by Centogene in collaboration with Denali Therapeutics in 2018, ROPAD (NCT03866603) is…
Cognitive function in adults with Parkinson’s disease either remains stable or progressively declines over time, according to a four-year follow-up study that also found that early problems with several tasks related to visual processing and spatial reasoning were among predictors of eventual cognitive impairments. Among Parkinson’s patients with cognitive…
Most people with Parkinson’s disease don’t experience dementia in the first decade after diagnosis, a study reported. The findings challenge long-held beliefs that dementia is a fairly common issue that tends to crop up early on in Parkinson’s patients. The study, “Long-Term Dementia Risk in…
Photopharmics said the first 100 patients have been enrolled in a Phase 3 trial testing its light-based therapy device, Celeste, to treat Parkinson’s disease. The Light for PD trial, which is expected to enroll 300 patients, is evaluating the device’s safety and efficacy at easing both motor and…
A new cell model of Parkinson’s disease is better able than others at capturing the complexity of the toxic protein clumps that characterize the disorder and to do so with useful speed, a study reports. “This technology will pave the way for rapidly developing ‘personalized stem cell models’ from…
The U.S. Food and Drug Administration (FDA) has approved Medtronic’s Asleep Deep Brain Stimulation (DBS) surgery for people with Parkinson’s disease or essential tremor. “This is a significant advancement in our surgical offering, providing another safe and effective option for patients considering DBS,” Amaza Reitmeier, a vice…
Recent Posts